AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Inclusion Criteria: * Age ≥18 years * Histologically confirmed CD30-positive lymphoma with cutaneous involvement * Failure or intolerance to at least one prior therapy for the current disease * Presence of one or more cutaneous lesions (measuring at least 1 cm x 1 cm in size; if only one lesion is present it should be up to the investigator discretion to determine eligibility) * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 * Adequate organ and marrow function * Platelets ≥50,000/μL * Absolute neutrophil count ≥ 1,000/μL * Bilirubin \< 1.5 x institutional upper limit of normal (ULN) or \< 3 x ULN in patients with Gilbert's disease or liver involvement * Serum albumin ≥ 2.0 g/dL * Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 × institutional ULN or, in the case of liver involvement by the primary disease AST/ALT ≤ 5 x ULN * Creatinine≤1.5 x institutional ULN or estimated creatinine clearance of ≥45 mL/min by the Cockcroft-Gault equation or measured creatinine clearance \>45 mL/min * Females of child bearing potential must have a negative serum pregnancy test with 7 days prior to first dose of treatment. Female patients of childbearing potential and all male partners must agree to use double barrier methods of contraception throughout the study period and for at least 30 days following investigational product discontinuation. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: *…